ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0797

Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease

Sarah Frey1, Caoilfhionn Connolly1, Teresa Po-Yu Chiang1, Mayan Teles1, Jennifer Alejo1, Jemima Albayda1, Lisa Christopher-Stine1, Dorry Segev2, William Werbel1 and Julie Paik1, 1Johns Hopkins University, Baltimore, MD, 2NYU Langone Health, New York, NY

Meeting: ACR Convergence 2022

Keywords: COVID-19, Epidemiology

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMD) treated with mycophenolate (MMF) have an attenuated humoral response to SARS-CoV-2 mRNA vaccination. A temporary hold of mycophenolate in the perivaccination period is associated with improved antibody response, prompting the American College of Rheumatology to recommend holding mycophenolate for one week after vaccine dose to enhance immunogenicity. The optimal duration of withholding therapy remains unknown. We sought to understand the impact of the duration of perivaccination mycophenolate hold on disease control (i.e. flare) and immunogenicity of SARS-CoV-2 vaccination in patients with RMD.

Methods: We leveraged an observational prospective cohort of RMD patients without prior COVID-19 who had received two mRNA SARS-CoV-2 vaccine doses. Demographic and clinical information was collected via electronic questionnaire. We included participants who reported MMF use. Serologic testing was undertaken on the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay (range 0.4-250U/mL, later expanded to >2500U/mL) at 2 weeks, 1 month and 3 months after dose 2 (D2); we utilized the highest available titer from any of these time points. Antibody response >250U/mL was defined as high titer. One-month post-D2, participants were invited to complete an online questionnaire detailing prior history of flare, incident flare events including symptoms, duration, and treatment; flare events were qualified as flares requiring treatment by a physician. Characteristics were compared using Wilcoxon rank-sum or Fisher’s exact test as appropriate; all tests were two-sided with an α level of 0.05. Analysis was conducted on Stata/SE17.0 (College Station, TX).

Results: Of 220 participants who reported MMF use, 177 (80.5%) did not withhold in the perivaccination period (Table 1). Among the 43 who did withhold MMF, 21 (48.8%) held for less than 10 days, while 22 (51.2%) held for at least 10 days. The median (IQR) days held in each group was 5 (2,7) and 21 (14, 30), respectively. A higher proportion of participants who held for at least ten days had a high antibody response compared to those who continued therapy or held for less than 10 days (64% [14/22] versus 29%[6/21] and 29% [51/177] respectively; p=0.006) (Table 2). There were similar rates of flare in the post-vaccination period in all groups (6.8%, 9.5%, and 4.5% respectively; p=1.00); none reported flare requiring intravenous therapy or hospital admission.

Conclusion: Longer duration of peri-vaccination mycophenolate hold is significantly associated with increased rates of high positive antibody response following two-dose SARS-CoV-2 vaccination. Reassuringly, there was not an increased rate of flare among participants who withheld therapy.

Supporting image 1

Table 1. Demographic and clinical characteristics, stratified by peri-vaccination mycophenolate hold duration.

Supporting image 2

Table 2. Anti-spike antibody response following two dose SARS-CoV_2 vaccine dose in RMD, stratified by peri-vaccination mycophenolate hold duration.


Disclosures: S. Frey, None; C. Connolly, None; T. Po-Yu Chiang, None; M. Teles, None; J. Alejo, None; J. Albayda, None; L. Christopher-Stine, Janssen, Boehringer-Ingelheim, Mallinckroft, EMD-Serono, Allogene, ArgenX; D. Segev, Sanofi, Novartis, Veloxis, Mallinckrodt, Jazz Pharmaceuticals, CSL Behring, Thermo Fisher Scientific, Caredx, Transmedics, Kamada, MediGO, Regeneron, AstraZeneca, Takeda, Bridge to Life; W. Werbel, None; J. Paik, Pfizer Inc, Kezar Inc, Roivant, Argenx, Alexion Inc.

To cite this abstract in AMA style:

Frey S, Connolly C, Po-Yu Chiang T, Teles M, Alejo J, Albayda J, Christopher-Stine L, Segev D, Werbel W, Paik J. Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/increased-duration-of-mycophenolate-hold-improves-antibody-response-to-sars-cov-2-vaccination-in-patients-with-rheumatic-and-musculoskeletal-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-duration-of-mycophenolate-hold-improves-antibody-response-to-sars-cov-2-vaccination-in-patients-with-rheumatic-and-musculoskeletal-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology